REGULATORY INTELLIGENCE · UPDATED JUNE 2026 · UKMC GROUP LTD
The ACMD review, CQC findings, GPhC pharmacy inspection, prescribing framework and regulatory risk — everything investors, family offices and private wealth owners need to understand about UK medical cannabis regulation in 2026 and what it means for capital allocation.
Published for informational purposes only. Does not constitute financial, legal, investment or regulatory advice. All data sourced from primary UK government and regulatory sources. Readers should seek independent professional advice before making any investment decision.
THE FRAMEWORK
The United Kingdom's medical cannabis regulatory framework is built on a deliberate and carefully maintained dual structure. Cannabis itself remains a Class B controlled substance under the Misuse of Drugs Act 1971. Possession, distribution and production outside authorised contexts remain criminal offences carrying potential custodial sentences. However, in November 2018 the UK Government rescheduled cannabis-based products for medicinal use from Schedule 1 to Schedule 2 under the Misuse of Drugs Regulations 2001 — enabling specialist doctors to prescribe them legally for the first time.
This dual structure — Class B for recreational purposes, Schedule 2 for medical prescribing — defines everything about how the UK market operates, how it is policed and how it will evolve. It is not a legalisation. It is a tightly bounded medical access framework operating within a prohibition context. For investors, this distinction is fundamental: the UK market exists and grows entirely within a private healthcare structure, almost entirely outside the NHS, and is subject to the oversight of multiple independent regulatory bodies simultaneously.
PRODUCT REGULATION
The MHRA is responsible for the marketing authorisation and quality standards of cannabis-based products for medicinal use (CBPMs). As of 2026, only three cannabis-derived products hold full MHRA marketing authorisation — Sativex (for MS spasticity), Epidyolex (for childhood epilepsy) and Nabilone (for chemotherapy-induced nausea). All other CBPMs are prescribed as unlicensed medicines under a specialist's clinical judgement — a legal route but one that comes with significant prescribing responsibility and documentation requirements. The MHRA's approach to unlicensed CBPM prescribing is under active review as part of the ACMD's wider process.
CLINIC REGULATION
The CQC regulates all health and social care services providing medical cannabis treatment in England. Every private medical cannabis clinic must be CQC registered. The CQC published its annual report on the Safer Management of Controlled Drugs in July 2025, which raised significant concerns about the rapid increase in medical cannabis prescriptions — noting a 130% rise in prescriptions dispensed by private clinics between 2023 and 2024. The CQC highlighted concerns including prescribing for conditions lacking strong clinical evidence and inappropriate advertising practices. CQC inspection findings are now a direct input into the ACMD review process.
PHARMACY REGULATION
The GPhC regulates pharmacies dispensing CBPMs. In October 2025 the GPhC published its themed review of pharmacies supplying CBPMs — inspecting 25 pharmacies regularly supplying cannabis-based products, of which 24 were operational at the time, analysing 68 concerns raised about CBPM management and supply. Governance was the most inconsistent area of compliance. Seven pharmacies failed to meet GPhC standards due to incomplete risk assessments and weak oversight of third-party prescribers. These findings are directly informing the ACMD review's assessment of whether current dispensing infrastructure is fit for purpose.
SCHEDULING & LICENSING
The Home Office retains control of cannabis scheduling under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001. All import licences for CBPMs are issued by the Home Office. The Home Office commissioned the ACMD review on 2 June 2025. Changes to scheduling — whether tighter or looser — require Home Office action following ACMD recommendations.
POLICY REVIEW
The ACMD is the independent scientific advisory body providing the UK Government with evidence-based recommendations on drug policy. The current ACMD review of the CBPM framework — commissioned June 2025, call for evidence closed October 2025 — is the most consequential regulatory process in UK medical cannabis since the 2018 rescheduling. Its findings will directly determine the regulatory environment for UK medical cannabis investment in 2027 and beyond.
THE ACMD REVIEW
Commissioned
2 June 2025 by the Home Office
Call for evidence
17 September – 17 October 2025
Review scope
Three-year comprehensive process
Expected findings
2026–2027 (exact date unconfirmed)
The Advisory Council on the Misuse of Drugs review is the most comprehensive reassessment of the UK's cannabis-based products for medicinal use framework since it was introduced in 2018. Commissioned by the Home Office on 2 June 2025, the sweeping three-year process aims to re-evaluate whether the UK's current system for prescribing, supplying and researching medical cannabis is fit for purpose — and whether it has achieved the objectives envisioned when cannabis was rescheduled from Schedule 1 to Schedule 2 nearly seven years ago.
The call for evidence ran from 17 September to 17 October 2025, inviting input from medical cannabis stakeholders including patients, specialists, researchers and clinics. The questionnaire covered the efficacy, safety and cost-effectiveness of CBPMs, the clinical outcomes achieved since 2018, the prescribing and dispensing environment, telemedicine practices, advertising and marketing conduct, and the broader social and public health impact of the 2018 rescheduling. All responses were anonymised.
The review is an extensive process that can take up to a year or longer until a final report and any regulatory changes are implemented.
Has the 2018 rescheduling achieved its intended goals of improving patient access to evidence-based cannabis medicine?
Are the current prescribing pathways and clinical oversight mechanisms adequate given the rapid growth in patient numbers and private clinic activity?
Are telemedicine platforms operating in a manner consistent with clinical best practice and patient safety?
Are pharmacy dispensing standards consistent and adequate across all CBPM-supplying pharmacies?
What regulatory changes — if any — are required to improve patient safety, clinical standards and prescribing oversight?
What are the unintended consequences of the 2018 framework — including any misuse, inappropriate prescribing or regulatory gaps?
TIGHTEN THE FRAMEWORK
The case for stricter regulation: the 130% prescription growth between 2023 and 2024 identified by the CQC, the GPhC finding that seven out of 25 inspected pharmacies failed governance standards, and the international precedent of Germany and Poland introducing telemedicine restrictions all point toward a tightening scenario. Under this vision, the ACMD recommends mandatory in-person initial consultations, stricter prescribing criteria, THC ceiling limits, tighter advertising restrictions and enhanced CQC oversight of clinic standards.
Investment implication: significant near-term disruption to clinic revenues, patient number growth slows, M&A accelerates as sub-scale operators exit.
EXPAND THE FRAMEWORK
The case for liberalisation: the 103% year-on-year market growth, 90,000–94,000 active patients (compared to 1–2% of the population in comparable markets such as Germany and Australia), strong real-world evidence of clinical benefit for chronic pain, PTSD and neurological conditions, and the significant private capital already deployed in clinic networks all point toward a cautiously expansive recommendation. Under this vision, the ACMD recommends improved NHS access pathways, clearer prescribing guidance, a formal real-world evidence framework and streamlined pharmacy dispensing standards.
Investment implication: patient growth accelerates, institutional capital enters the market, clinic valuations expand.
"At the heart of the ACMD review is a set of binary policy inflection points. The path chosen will echo for a decade."
PHARMACY STANDARDS
Pharmacies inspected in the GPhC 2025 themed review of CBPM-supplying pharmacies. Source: GPhC 2025.
Concerns analysed regarding CBPM management and supply across inspected pharmacies. Source: GPhC 2025.
Pharmacies that failed GPhC standards due to incomplete risk assessments and weak oversight of third-party prescribers. Source: GPhC 2025.
Area of compliance identified as most inconsistently met across all inspected pharmacies: governance. Source: GPhC 2025.
The GPhC's October 2025 themed review of pharmacies supplying cannabis-based products for medicinal use is the most detailed regulatory snapshot yet of how medical cannabis is being dispensed across the UK. Commissioned in parallel with the ACMD's wider policy review, it exposed wide variation in compliance, governance and clinical oversight across a sector still dominated by private prescribing.
The GPhC analysed 68 concerns raised about CBPM management and supply across the 25 inspected pharmacies. Governance was identified as the most inconsistent area of compliance — seven pharmacies failed to meet GPhC standards due to incomplete risk assessments and weak oversight of third-party prescribers. Other areas of concern included record-keeping, patient counselling standards and the management of controlled drug registers. The GPhC's findings will be central to the ACMD's assessment of whether the 2018 rescheduling has achieved its intended outcomes and whether new safeguards or system reforms are required. Source: GPhC 2025 themed review, General Pharmaceutical Council.
For investors: the GPhC findings signal that pharmacy compliance infrastructure is likely to be a key focus of any regulatory reform package. Operators whose clinic and pharmacy networks have robust governance, documented risk assessments and strong oversight of third-party prescribers are better positioned under any regulatory outcome than those with weaker compliance infrastructure.
CQC FINDINGS
The Care Quality Commission's July 2025 annual report on the Safer Management of Controlled Drugs provided the clearest official view yet of how rapidly the UK medical cannabis market has grown — and the regulatory concerns that growth has generated.
The CQC noted a 130% rise in prescriptions dispensed by private clinics between 2023 and 2024. The CQC indicated that this substantial growth was concerning due to a perceived lack of oversight regarding prescribers. Source: CQC, Safer Management of Controlled Drugs Annual Report, July 2025.
According to the CQC, 99.5% of medical cannabis prescriptions in 2024 were issued in independent private healthcare settings. NHS prescribing of CBPMs remains almost non-existent, with only three products holding full MHRA marketing authorisation. Source: CQC 2024 data cited in Prohibition Partners Global Medical Cannabis Market Review 2026.
The CQC specifically raised concerns about the prescribing of medical cannabis for conditions that lacked strong, justifiable evidence of efficacy — a finding that directly mirrors the concerns that triggered telemedicine restrictions in Germany and Poland and that is likely to be central to the ACMD's recommendations. Source: CQC, July 2025.
The CQC identified inappropriate advertising activities as a regulatory concern among UK private medical cannabis clinics. This mirrors the enforcement actions taken by the TGA in Australia — where between 2022 and June 2024 the TGA issued 165 infringement notices for alleged unlawful medicinal cannabis advertising, resulting in over AUD $2.3 million in penalties. Source: CQC July 2025; TGA Australia 2024.
PRESCRIBING RULES
Under the current framework, medical cannabis can only be prescribed in the UK by a specialist doctor — a clinician who has completed specialist training in their relevant field and who holds appropriate GMC registration. General practitioners cannot prescribe CBPMs. The prescribing doctor must assess whether conventional treatments have been tried and have failed, whether there is a clinical evidence base for cannabis medicine in the patient's condition, and whether the benefits outweigh the risks for that specific patient.
The prescribing process in 2026 typically involves:
Either in-person or via video call (telemedicine). The specialist reviews medical history, previous treatments, current symptoms and contraindications. The consultation typically lasts 45 minutes to one hour. Initial consultation fees across UK private clinics range from £50 to £200 depending on the provider.
Many UK clinics require peer review of the initial prescription by a second specialist before the prescription is issued. This is a UK-specific requirement that distinguishes the UK model from Germany's post-CanG framework, where any doctor can prescribe via e-prescription without peer review.
The specialist issues a private prescription for a specific CBPM — typically a flower, oil or vape product. Prescriptions must be dispensed by a pharmacy holding a Home Office controlled drug licence. In 2025, there were 628 unique CBPM SKUs available in the UK at an average flower price of £7.05 per gram. Source: MedBud.wiki, Prohibition Partners 2026.
The pharmacy dispenses the CBPM and delivers it to the patient. UK pharmacies can use mail-order delivery — unlike the mail-order ban proposed in Germany's MedCanG amendments. This is a structural advantage of the UK model that investors should note.
Follow-up consultations are required at intervals depending on the clinic model. Clinic models vary significantly — Releaf operates a monthly subscription model with unlimited clinical access, while Mamedica operates a low-frequency annual review model at £75 per year after onboarding.
INVESTOR RISK SCENARIOS
WHAT IT MEANS
The ACMD recommends improved clinical guidelines, better prescribing documentation and enhanced pharmacy governance — but no structural change to the telemedicine model or prescribing pathway. The 2018 framework remains substantively intact.
INVESTMENT IMPLICATION
Patient growth continues at current trajectory. Clinic network investment remains attractive. UK market approaches £500 million by 2027. Supply chain operators, technology platforms and compliant clinic networks all benefit. This is the most positive scenario for existing investors.
WHAT IT MEANS
The ACMD recommends mandatory in-person initial consultations, tighter prescribing criteria for specific conditions, enhanced CQC oversight of clinic advertising and stricter pharmacy governance standards. Telemedicine continues for follow-up and repeat prescriptions.
INVESTMENT IMPLICATION
Modelled on Poland's telemedicine restriction experience — prescriptions decline 25–40% in the short term as patient access pathways adjust, before recovering as hybrid clinic models emerge. Clinic operators with physical infrastructure and established patient bases outperform digital-only platforms. M&A accelerates. Sub-scale operators with weaker compliance exit the market. Net medium-term outcome: a more defensible, institutionally investable market.
WHAT IT MEANS
The ACMD recommends mandatory in-person initial consultations, mail-order pharmacy restrictions, THC ceiling limits and significant reduction in conditions eligible for CBPM prescribing. A near-replication of Germany's proposed MedCanG amendments applied to the UK context.
INVESTMENT IMPLICATION
Severe short-term market contraction. Patient numbers could decline 40–50% within six months. Clinic revenues fall sharply. Supply chain operators face inventory and margin pressure from reduced demand. However — as Poland demonstrated — recovery begins within two to three quarters as hybrid models emerge. Long-term: the remaining compliant operators become significantly more valuable as the market reconstitutes around a smaller, higher-quality operator base. Investors with patient capital and strong portfolio operators benefit from consolidation.
Scenario modelling is for informational purposes only and does not constitute investment advice. All scenario analysis is derived from the documented outcomes of comparable regulatory changes in Poland (November 2024) and proposed regulatory changes in Germany (October 2025 onward). Source: Prohibition Partners Global Medical Cannabis Market Review 2026; Centrum e-Zdrowia Poland 2025.
MONITORING FRAMEWORK
The ACMD review timeline is a three-year process from its June 2025 commissioning, but interim findings and final recommendations could arrive as early as late 2026. The publication date of the ACMD's final report is the single most important date in the UK medical cannabis investment calendar for 2026 and 2027. Monitor: gov.uk/government/organisations/advisory-council-on-the-misuse-of-drugs
Germany's proposed telemedicine and mail-order restrictions are expected to receive further Bundestag readings and a vote in spring 2026. The outcome will directly influence UK regulatory thinking — if Germany's restrictions cause the predicted 25–50% market contraction, UK policymakers and the ACMD will be watching the consequences closely. A German restriction that causes significant harm to patients is likely to influence the ACMD toward a more cautious approach to UK telemedicine restrictions.
The CQC's programme of inspections of private medical cannabis clinics is ongoing and accelerating. Any clinic receiving a 'Requires Improvement' or 'Inadequate' rating faces immediate regulatory consequences and potential patient transfer. Monitor the CQC register at: cqc.org.uk for new inspection reports on named clinics.
Following the October 2025 themed review findings, the GPhC is likely to take formal enforcement action against pharmacies that failed governance standards. Any pharmacy losing its CBPM dispensing licence is a material event for the clinic networks it serves. Monitor: pharmacyregulation.org
The MHRA is reported to be considering stricter oversight of the unlicensed CBPM prescribing pathway. Any MHRA guidance restricting the conditions under which CBPMs can be prescribed as unlicensed medicines would have immediate and significant market implications. Monitor: gov.uk/mhra
THE SUMMIT
The UK Medical Cannabis Investment Summit 2027 brings together investors, family offices, policymakers, clinicians and industry leaders to discuss the regulatory developments — including the ACMD review outcome — that will define UK medical cannabis investment returns in 2027 and beyond. Two days. London. June 2027.
FREQUENTLY ASKED QUESTIONS
IMPORTANT NOTICE: This page is published by UKMC Group Ltd for informational purposes only. Nothing on this page constitutes financial, investment, legal or regulatory advice. All regulatory data is sourced from UK Government and regulatory body primary sources as cited throughout. Regulatory conditions change — readers should verify current information independently and seek qualified professional advice before making any investment decision. © 2026 UKMC Group Ltd.